Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer

Inclusion Criteria:

* Histologically/cytologically confirmed unresectable locally advanced pancreatic adenocarcinoma.
* Measurable disease by RECIST criteria must be present.
* Karnofsky Performance Status ≥ 70
* Patients with adequate organ functions reflected by the laboratory criteria below:

Granulocytes ≥ 1,500/uL Hemoglobin ≥ 8.0 gm/dL Platelets ≥ 100,000/uL Serum creatinine \< 2.0 mg/dL Bilirubin \< 1.5 mg/dL SGPT \< 2.5 x normal Alk Phos \< 2.5 x normal

* Prior local therapy, e.g., radiation, is allowed provided that at least 4 weeks washout time is given.
* Patients with jaundice must have a biliary drainage decompression operation before recruitment.
* Patients must not be pregnant. Serum beta-HCG will be checked in all premenopausal patients.
* Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

* Subject with metastatic disease.
* Prior treatment with systemic chemotherapy.
* Known allergies to the gemcitabine, oxaliplatin or iodine contrast agent.
* Subject with Child-Pugh grade Class C hepatic impairment, active gastrointestinal bleeding, severe coagulation disorder that could not be corrected，or other contraindication for transcatheter infusion.
* Untreated or uncontrolled deep vein thrombosis, arterial thrombosis of lower extremity, or aneurysm.
* Concurrent infection requiring intravenous antibiotics.
* Skin injury or infection of groin area, or other situation that not appropriate for femoral artery puncture.
* Other serious illness or condition including cardiac disease including congestive heart failure (New York Heart Association Classification III or IV), active HIV infection/HIV disease, psychiatric disorders.
* Known central nervous system involvement and leptomeningeal disease
* Subject with previous or concurrent cancer that is distinct in primary site or histology from pancreatic adenocarcinoma except cervical carcinoma in situ, non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer curatively treated greater than 3 years prior to entry is permitted.
* Pregnant or lactating women.